Last updated: February 13, 2026
Overview
NDC 00054-0080 is a medication marketed by Eli Lilly, identified as Olumiant (baricitinib). Approved by the FDA for rheumatoid arthritis and recent emergency use authorizations for COVID-19, it operates as a Janus kinase (JAK) inhibitor. Despite its initial target indications, its potential as a treatment for COVID-19 and other inflammatory condition candidates impacts its market trajectory.
Current Market Landscape
Indications & Approvals
- FDA Approval: Rheumatoid arthritis (2018)
- Emergency Use Authorization: COVID-19 (2021, EUA granted, later revoked)
- Off-label & Investigational Uses: Autoimmune diseases, dermatologic conditions
Competitive Positioning
| Drug Class |
Key Competitors |
Market Share (2022) |
Pricing Range (per 30-day supply) |
| JAK inhibitors |
Upadacitinib (Rinvoq), tofacitinib (Xeljanz) |
70% |
$2,300 - $4,600 |
| Biologics |
Adalimumab, etanercept |
Remaining 30% |
Varies, typically $2,000 - $5,000 |
Market Drivers
- Growing prevalence of rheumatoid arthritis (~1.3 million in the US)
- COVID-19 treatment landscape shifting post-EUA revocation
- Expansion into other autoimmune conditions
Note: The EUA status of baricitinib was revoked in 2022 due to limited efficacy data for COVID-19, shifting focus back to its RA indication.
Market Size and Revenue Projections
Annual Revenue Estimates (2022-2027)
| Year |
Estimated U.S. Market Revenue |
Global Market Revenue |
Notes |
| 2022 |
$150 million |
$600 million |
Post-EUA revocation, decline in COVID-19 indications |
| 2023 |
$200 million |
$700 million |
Focus on RA, expansion in dermatology |
| 2024 |
$250 million |
$900 million |
Possible new approvals or expanded indications |
| 2025 |
$350 million |
$1.2 billion |
Increased adoption, pricing strategies |
| 2026 |
$400 million |
$1.4 billion |
Competition from newer JAK inhibitors |
| 2027 |
$420 million |
$1.5 billion |
Market maturation, potential biosimilars |
Market Growth Factors
- Increased use in rheumatoid arthritis, chronic dermatologic conditions
- Potential approvals for broader autoimmune applications
- Competitive pressure from Rinvoq and Xeljanz—price adjustments and formulary placements influence revenue
Pricing Dynamics and Future Trends
Current Pricing
- Average retail price: approximately $3,500 for a 30-day supply (based on available data)
- Insurance rebates and discounts reduce net price; net prices estimated at $2,800–$3,200
Factors Impacting Future Prices
- Entry of biosimilars or generics could reduce prices by up to 50%
- Price negotiations with payers could lead to discounts
- Each new indication could influence pricing via formulary placement and patent protections
Pricing Projections
By 2025, pricing could stabilize at a range of $2,800–$3,200 per month, assuming biosimilar competition remains limited. If biosimilars enter the market, prices could decrease by 30–50% within three years.
Regulatory and Patent Landscape
Patent Portfolio
- Key patents expire between 2023–2027, opening pathways for generic entry
- Eli Lilly actively defends its intellectual property with litigation and patent filings
Market Access & Reimbursement
- Payers favor cost-effective JAK inhibitors; formularies tend toward Rinvoq and Xeljanz
- Price negotiations will influence net revenue and market penetration
Key Opportunities and Risks
Opportunities
- Expanding indications into dermatology and inflammatory bowel disease
- Collaboration with generic manufacturers for early biosimilar entry
- Potential re-approval or new indications for COVID-19 or future pandemics
Risks
- Market saturation as competitors introduce alternative JAK inhibitors
- Patent expiries leading to increased generic competition
- Regulatory uncertainties affecting expansion into new indications
Summary
NDC 00054-0080, primarily marketed as Olumiant (baricitinib), faces a competitive environment where pricing and market share are heavily affected by patent protections and biosimilar developments. Currently, its revenue is estimated at approximately $150–200 million in the US, with global revenues reaching up to $700 million in 2023. Prices are moderated by competitive pressures, with an expected stabilization around $3,000 per month. Long-term growth hinges on expanding indications and navigating patent protections.
Key Takeaways
- The drug’s primary market is rheumatoid arthritis, with recent declines in COVID-19-related sales.
- Prices likely to stay within the $2,800–$3,200 range unless biosimilars significantly impact the market.
- Revenue growth from 2023 onward will depend on new indications and patent protections.
- Competition from other JAK inhibitors is intensifying, influencing pricing strategies.
- Patent expiries from 2023 could alter market dynamics.
FAQs
1. How does bioavailability affect the pricing of NDC 00054-0080?
Bioavailability influences dosing frequency and effectiveness, which indirectly affects manufacturing costs. However, pricing is primarily driven by market competition, patent status, and payer negotiations.
2. What are the main competitors for this drug?
Rinvoq (upadacitinib) and Xeljanz (tofacitinib) are the primary competitors within the JAK inhibitor class, with similar indications and comparable pricing.
3. How does patent expiry impact market projections?
Patent expiries from 2023–2027 enable biosimilar or generic manufacturing, likely reducing prices and market share for the originator drug.
4. What future indications could expand the market size?
Potential applications include dermatologic conditions like atopic dermatitis and inflammatory bowel diseases, subject to clinical trial results and approvals.
5. How do insurance formularies influence the drug’s market penetration?
Formularies prefer cost-effective therapies; the positioning of Olumiant relative to competitors affects prescribing patterns and overall revenue.
Sources
[1] FDA Label Information for Olumiant.
[2] IQVIA Market Data, 2022.
[3] Eli Lilly Annual Reports, 2022.
[4] Pharmaceutical Price Index, 2023.
[5] Market Research Insights, 2022–2023.
